Mar 14, 2019 / 02:15PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst
Good morning. Welcome to the third day of the Barclays Global Healthcare Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here. And I have Kristen Stewart, our med device analyst up on stage as well. So we're thrilled to have Johnson & Johnson. And we have Tom Cavanaugh, who is President of Oncology, here to my right; and then Catherine Owen is President of Immunology to my right. And my -- to my left here is Chris DelOrefice from the IR team; and then Lesley Fishman, who's also from the IR team.
So we're just going to do a fireside chat today. But I think, Lesley, you wanted to read out the forward-looking statement, and then we can get right into it.
Lesley Fishman -
Thank you, Geoff. I promise to be brief. Please be aware that some statements made today may be considered forward-looking. Please refer to our SEC filings, in particular our 10-K, which discuss risks and uncertainties that could cause results to differ materially from
Johnson & Johnson at Barclays Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot